The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group

På svenska

Author

  • Richard M. Brohet
  • David E. Goldgar
  • Douglas F. Easton
  • Antonis C. Antoniou
  • Nadine Andrieu
  • Jenny Chang-Claude
  • Susan Peock
  • Rosalind A. Eeles
  • Margaret Cook
  • Carol Chu
  • Catherine Nogues
  • Christine Lasset
  • Pascaline Berthet
  • Hanne Meijers-Heijboer
  • Anne-Marie Gerdes
  • Håkan Olsson
  • Trinidad Caldes
  • Flora E. van Leeuwen
  • Matti A. Rookus
Show all

Summary, in English

Purpose Earlier studies have shown that endogenous gonadal hormones play an important role in the etiology of breast cancer among BRCA1/ 2 mutation carriers. So far, little is known about the safety of exogenous hormonal use in mutation carriers. In this study, we examined the association between oral contraceptive use and risk of breast cancer among BRCA1/ 2 carriers. Patients and Methods In the International BRCA1/ 2 Carrier Cohort study ( IBCCS), a retrospective cohort of 1,593 BRCA1/ 2 mutation carriers was analyzed with a weighted Cox regression analysis. Results We found an increased risk of breast cancer for BRCA1/ 2 mutation carriers who ever used oral contraceptives ( adjusted hazard ratio [ HR] = 1.47; 95% CI, 1.16 to 1.87). HRs did not vary according to time since stopping use, age at start, or calendar year at start. However, a longer duration of use, especially before first full- term pregnancy, was associated with an increased risk of breast cancer for both BRCA1 and BRCA2 mutation carriers ( 4 or more years of use before first full-term pregnancy: HR = 1.49 [ 95% CI, 1.05 to 2.11] for BRCA1 carriers and HR = 2.58 [ 95% CI, 1.21 to 5.49] for BRCA2 carriers). Conclusion No evidence was found among BRCA1/ 2 mutation carriers that current use of oral contraceptives is associated with risk of breast cancer more strongly than is past use, as is found in the general population. However, duration of use, especially before first full- term pregnancy, may be associated with an increasing risk of breast cancer among both BRCA1 and BRCA2 mutation carriers.

Department/s

Publishing year

2007

Language

English

Pages

3831-3836

Publication/Series

Journal of Clinical Oncology

Volume

25

Issue

25

Document type

Journal article

Publisher

American Society of Clinical Oncology

Topic

  • Cancer and Oncology

Keywords

  • Oral Contraceptives Breast Cancer International BRCA1/2 EMBRACE GENEPSO GEO-HEBON IBCCS

Status

Published

ISBN/ISSN/Other

  • ISSN: 1527-7755